AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: AstraZeneca is conducting a Phase III study titled A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis). The study aims to evaluate the efficacy and safety of anifrolumab in treating moderate to severe idiopathic inflammatory myopathies, specifically polymyositis and dermatomyositis, while patients continue their standard care.
Intervention/Treatment: The study tests the intervention of anifrolumab, administered as a subcutaneous injection once weekly. Anifrolumab is compared against a placebo, with both groups receiving standard care. The treatment aims to reduce disease activity in patients.
Study Design: This is an interventional, randomized, placebo-controlled, double-blind study with a parallel assignment. The study involves quadruple masking, meaning the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose is treatment-focused.
Study Timeline: The study began on June 20, 2024, with an estimated primary completion date yet to be announced. The last update was submitted on June 30, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
Market Implications: The ongoing study could significantly impact AstraZeneca’s stock performance and investor sentiment, especially if anifrolumab proves effective. Success in this study may enhance AstraZeneca’s competitive position in the market for treatments of idiopathic inflammatory myopathies, potentially affecting competitors in the pharmaceutical industry.
The study is currently recruiting, with further details available on the ClinicalTrials portal.